Overview

A Renal Impairment Study for PF-04965842

Status:
Completed

Trial end date:
2019-11-05

Target enrollment:

Participant gender:

Summary

This study is a phase 1 non-randomized, open-label, single-dose, parallel-group study of PF 04965842 in subjects with severe renal impairment and subjects without renal impairment (Part 1) and in subjects with moderate renal impairment (Part 2).

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Abrocitinib